TY  - JOUR
T1  - COsts and benefits of male circumcision
AU  - Hay JW
Y1  - 2013/02/01
N1  - 10.1001/jamapediatrics.2013.829
JO  - JAMA Pediatrics
SP  - 198
EP  - 198
VL  - 167
IS  - 2
N2  - 
Kacker et al1 present an economic model to justify Medicaid covering newborn male circumcision (MC) in the United States. However, their model uses highly flawed assumptions and projections. About 79% of their savings are MC-attributed reductions in human immunodeficiency virus (HIV) sexual transmission (only beginning about 12 years after enhanced MC coverage), but their base case lifetime cost of treating HIV/AIDS ($388 754) derives from estimates with highly active antiretroviral therapy (HAART) using brand name prices. In 12 years, most of these HAART medications will be generic.

SN  - 2168-6203
M3  - doi: 10.1001/jamapediatrics.2013.829
UR  - http://dx.doi.org/10.1001/jamapediatrics.2013.829
ER  -